There is a knowledge gap in screening and management strategies for osteoporosis in patients undergoing GLP-1Ra
It is an effective weight loss drug, functioning by mimicking a satiety hormone, reducing appetite, and slowing gastric emptying
With regard to the increased secretion of EVs during the progression of NAFLD, experimental studies demonstrated that toxic lipids significantly increase the production of hepatocyte-derived EVs, which act as mediators of paracrine signaling, causing hepatic stellate cell activation, angiogenesis and activation of macrophages leading to inflammation and chemotaxis [103,104,105]
No, liraglutide and semaglutide are not indicated for patients with type 1 diabetes
According to the Ozempic SmPC, use is not recommended in patients with severe gastrointestinal disease, including severe gastroparesis